Novo Nordisk flags board members for re-election amid restructuring efforts

In a bid to regain operational stability, Novo Nordisk’s Board of Directors has nominated 2 caller members to articulation the committee, which has been undergoing a revamp successful caller months.

Jan van de Winkel and Ramona Sequeira would some service a one-year word if elected by shareholders successful an Annual General Meeting, which volition beryllium held connected 26 March.

Having worked successful the pharma manufacture for much than a 4th of a century, van de Winkel has held C-suite roles crossed pharma and biotech – serving arsenic the VP and technological manager of Medarex Europe anterior to co-founding therapeutic antibody-focused biotech, Genmab. Since then, helium has occupied varying high-level positions astatine the company, including his existent relation arsenic CEO, which helium entered successful 2010.

Meanwhile, Sequeira has spent much than 3 decades successful pharma enactment roles crossed companies similar Eli Lilly and Takeda Pharmaceutical. Between 2022 and Summer 2025, Sequeira was the president of Takeda’s planetary portfolio division, and she presently serves arsenic a committee subordinate for some Organon and Edwards Lifesciences.

Novo Nordisk’s committee is besides calling for the re-election of Lars Rebien Sørensen and Cees de Jong arsenic seat and vice chair, respectively, arsenic good arsenic Britt Meelby Jensen, Kasim Kutay and Stephan Engels arsenic members.

Alongside the board’s recommendations, Novo Nordisk’s bulk shareholder, The Novo Nordisk Foundation, has enactment guardant Helena Saxon arsenic its recommendation. Saxon antecedently held a committee presumption for 14 years astatine Swedish biopharma company, Sobi, earlier her resignation successful October 2025. She presently sits connected the committee of the planetary retail brand, H&M.

Novo Nordisk’s determination to clasp a committee re-election follows a play of important alteration for the committee, which saw a wide exodus successful October 2025 erstwhile 7 members stood down. This was mostly owed to a disagreement betwixt the committee and its bulk shareholder, the Novo Nordisk Foundation, connected the council’s aboriginal composition.

If nominated, van de Winkel, Sequeira and Saxon would articulation a committee of mostly caller appointees, who are looking to crook the company’s fortunes circular arsenic it grapples with contention from Eli Lilly successful the cardiometabolic market. Currently, Novo Nordisk forecasts a income dip of up to 13% successful 2026 owed to Most Favored Nation (MFN)-driven pricing headwinds successful the US.

While the institution has a caput commencement successful the oral glucagon-like peptide 1 receptor agonist (GLP-1RA) marketplace done its first-to-market support of oral Wegovy (semaglutide), Lilly’s orforglipron is slated to participate the marketplace successful April this year, with a patient-based forecast from GlobalData estimating that the cause volition bring successful $14.3bn successful 2031.